Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:05:24.537Z.
Calculation as of: 2026-10-06T15:05:24.537Z.
Quote observation: 2026-10-06T15:05:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6c856baf2af26ca9326fa79b8c43a58fbb1378fdf70f4049426595b89831cd0b
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Absci Corporation (ABSI) | $1.85B | N/A | N/A | N/A | N/A |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 28.02 | 37.26 | 45.15 | 45.92 |
| Novocure Ltd (NVCR)vs › | $1.84B | N/A | 1067.41 | 1002.04 | 1002.04 |
| Astrana Health, Inc. (ASTH)vs › | $1.84B | 45.45 | 79.20 | 49.35 | 42.48 |
| Novavax, Inc. (NVAX)vs › | $1.87B | N/A | 3.65 | 3.65 | 3.65 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | N/A | 3.28 | 3.28 | 3.28 |
| Generate Biomedicines, Inc. (GENB)vs › | $1.78B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 37.72 | 35.65 | 35.65 | 327.33 |
| Azenta, Inc. (AZTA)vs › | $1.91B | N/A | 61.77 | 49.90 | 40.42 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.72B | N/A | 23.72 | 50.63 | 57.39 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$10.93
Forward EPS (Est.)
$-0.80
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
